Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence of immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies and some patients even experience severe adverse events. Prognostic and predictive bioma...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (8), p.7577
Main Authors: Pabst, Lucile, Lopes, Sébastien, Bertrand, Basil, Creusot, Quentin, Kotovskaya, Maria, Pencreach, Erwan, Beau-Faller, Michèle, Mascaux, Céline
Format: Article
Language:English
Subjects:
B7-H1 Antigen - metabolism
Biological markers
Biomarkers, Tumor - metabolism
Cancer
Care and treatment
Health aspects
Humans
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Immunotherapy - methods
Lung cancer
Lung Neoplasms - drug therapy
Prognosis
Review
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence of immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies and some patients even experience severe adverse events. Prognostic and predictive biomarkers are therefore needed in order to select patients who will respond. Nowadays, the only validated biomarker is the PD-L1 expression, but its predictive value remains imperfect, and it does not offer any certainty of a sustained response to treatment. With recent progresses in molecular biology, genome sequencing techniques, and the understanding of the immune microenvironment of the tumor and its host, new molecular features have been highlighted. There are evidence in favor of the positive predictive value of the tumor mutational burden, as an example. From the expression of molecular interactions within tumor cells to biomarkers circulating in peripheral blood, many markers have been identified as associated with the response to immunotherapy. In this review, we would like to summarize the latest knowledge about predictive and prognostic biomarkers of immune checkpoint inhibitors efficacy in order to go further in the field of precision immuno-oncology.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms24087577